After single exit, Avalon seeks path forward for build-to-buy assets from GSK deal

Avalon is shopping four assets now that GSK has moved on from a build-to-buy deal

With GSK effectively bowing out of a 2013 build-to-buy deal with Avalon Ventures after delivering just one exit, the VC is seeking to navigate a future for a handful of Phase I-ready programs it created to fill the pipeline of a partner that has since moved on.

A deal announced Wednesday, in which GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) acquired celiac disease company

Read the full 603 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE